课题基金 / 基金详情

Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's

Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's
加速药物合作 - 自身免疫和免疫疾病组织研究核心管理补充:干燥病的临床前研究
批准号:
10834635
负责人:
Joel Marvin Guthridge
金额:
$146.04万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-23 至 2026-12-31
关键词:
AccelerationAddressAffectAlgorithmsAntibodiesAntigensArthritisAutoantibodiesAutoimmune DiseasesAutomobile DrivingAutophagocytosisB-Cell LymphomasB-Lymphocyte SubsetsB-LymphocytesBiological MarkersBiological Response Modifier TherapyBiopsyBloodCCR6 geneCD4 Positive T LymphocytesCRISPR interferenceCRISPR-mediated transcriptional activationCXCR3 geneCell DeathCell SeparationCellsChromiumChronicClassificationClinicClinicalClinical TrialsCluster AnalysisConduct Clinical TrialsCytometryDataData SetDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDrynessEconomic BurdenEnhancersEnsureEpithelial CellsEpitheliumExclusionFatigueFibroblastsFibrosisFlow CytometryFunctional disorderGeneticGenomicsGlandGoalsHLA-DR AntigensHaplotypesHeterogeneityHumanImageImmuneImmune System DiseasesImmunologyIn VitroIndividualInterviewInvestigationLabial Salivary GlandLip structureLungLymphocyteLymphomaMachine LearningMapsMedicineMethodsMolecularMonitorMultiomic DataNatureNeuropathyPainPathogenicityPathologyPatient RecruitmentsPatientsPeripheral Blood Mononuclear CellPersonsPhenotypePlasmaPopulationPositioning AttributeProbabilityProcessProteinsProteomeProteomicsResearchResearch PersonnelRheumatismRheumatologyRiskRoleSS-A antibodiesSalivaSalivary GlandsSerumSialadenitisSjogren&aposs SyndromeSortingSourceSurrogate MarkersT-LymphocyteT-Lymphocyte SubsetsTechnologyTelephoneTestingTissuesTranscriptional RegulationUntranslated RNAVasculitisXerostomiaantibody diagnosticautoimmune exocrinopathycell typeclinical developmentclinical heterogeneitycohortdata reductiondeep learningdiagnostic accuracydiagnostic assaydiagnostic biomarkerdisorder controleye drynessfeature selectiongenetic associationgradient boostinghealth care settingsimprovedinsightmachine learning methodmeetingsmultidisciplinarymultiple omicsmultiplex diagnosticsnano-stringneural networknew therapeutic targetnoninvasive diagnosisnovelpatient subsetspreclinical studyprogrammed cell death protein 1random forestrheumatologistrisk variantscreeningsingle-cell RNA sequencingsupport vector machinetooltranscriptometranscriptomics

项目摘要

项目成果

Joel Marvin Guthridge的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT ABSTRACT Sjögren’s syndrome (SS) is an incapacitating rheumatic disease typified by severe dry eyes and mouth, often including arthritis, debilitating fatigue, pulmonary involvement, neuropathy, vasculitis and malignant lymphoma. The personal and economic burdens ($35 billion/year in the US) are high, and there is no effective biologic therapy. Lack of understanding of basic disease processes, molecular underpinnings of patient heterogeneity, and effective diagnostic biomarkers have hindered the development of effective biologic therapies and conduct of successful clinical trials. This is especially true for patients lacking anti-Ro antibodies (Ro– SS) who require a salivary gland biopsy for classification. We are in a unique position to study the differences between Ro+ and Ro– SS. In our carefully phenotyped cohort, nearly 40% of SS patients meeting current classification criteria lack diagnostic anti-Ro autoantibodies. Our Ro– SS cases have more glandular, articular, and pulmonary involvement than Ro+ SS cases, yet these patients are often not diagnosed by rheumatologists or included in clinical trials. Herein, we leverage our multidisciplinary team of investigators with expertise in rheumatology, immunology, genomics/genetics, as well as our carefully phenotyped cohort of 668 SS cases and 925 non-SS sicca patients to address these deficiencies. The project is based on compelling preliminary data identifying common and unique features in both Ro+ and Ro– SS groups and will study a common set of 60 Ro+ SS cases, 60 Ro– SS cases, and 24 healthy controls. Aim 1 will develop and apply an autoantibody-based diagnostic test for Ro– and Ro+ SS and leverage salivary gland proteomics, spectral flow cytometry, imaging mass cytometry, and functional studies to clarify the role of T and B cell subsets in disease. Aim 2 will employ single cell RNA-seq of PBMC and sorted cells studied in Projects 1 and 2, identify chromosomal interactions in primary salivary gland epithelial cells, study functional effects of Ro+ and Ro– SS risk alleles and long non-coding RNAs using CRISPR interference or activation for enhancers, and use feature selection and machine learning to identify sources of heterogeneity between Ro+ and Ro– SS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
  • 批准号:
    10655219
  • 项目类别:
  • 资助金额:
    $129.11万
  • 财政年份:
    2023
  • 负责人:
    Joel Marvin Guthridge
  • 依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
海外基金